Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Sarcoma 9Myelodysplastic Syndromes 9Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Lung Neoplasms 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3

Interventions

enzalutamide 4cabazitaxel 3Docetaxel 3Prednisone 2talazoparib 1rucaparib 1pembrolizumab 1olaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1Radiosurgery 1Positron Emission Tomography Computed Tomography 1LY3023414 1Injections 1Carboplatin 1Abituzumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Prostate Cancer Metastatic × Injections × Clear all
NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Modra Pharmaceuticals

Phase 2 Completed
135 enrolled 29 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡